ATENT COOPERATION TRL .TY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference RLL-338WO	FOR FURTHER A	CTION	See Form PCT/IPEA/416		
International application No. PCT/IB2004/000536	International filing date 01.03.2004	(day/month/year)	Priority date (day/month/year) 28.02.2003		
International Patent Classification (IPC) or national classification and IPC A61K9/20, A61K9/30, A61K31/4439					
Applicant RANBAXY LABORATORIES LIMI	ITED et al.				
 This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36. 					
2. This REPORT consists of a tota	. This REPORT consists of a total of 5 sheets, including this cover sheet.				
3. This report is also accompanied	by ANNEXES, comprising	ng:			
a. 🛛 sent to the applicant and	to the International Bure	eau) a total of 3 sheets	, as follows:		
and/or sheets contain	sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).				
☐ sheets which supers beyond the disclosur Supplemental Box.	beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the				
b. (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)), containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).					
This report contains indications in	relating to the following it	ems:			
☐ Box No. I Basis of the op	pinion				
☐ Box No. II Priority					
☐ Box No. III Non-establishr	nent of opinion with rega	rd to novelty, inventive	step and industrial applicability		
☐ Box No. IV Lack of unity o	f invention				
	ement under Article 35(2 tations and explanations		, inventive step or industrial nent		
☐ Box No. VI Certain docum					
	s in the international appl				
☐ Box No. VIII Certain observ	ations on the internationa	al application			
Date of submission of the demand		Date of completion of the	s report		
23.12.2004		08.04.2005			
Name and mailing address of the internatio	nal	Authorized Officer	, has Polonzo.		
European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465		Hedegaard, A Telephone No. +49 89 2	399-8644		

10/547200

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/IB2004/000536

			DIU9 Rec'd PCT/PTO 26 AUG 2005		
_	Box No.	I Basis of the report			
1	With regard to the language , this report is based on the international application in the language in which it values of the regard to the language in which it values of the regard to the language in which it values of the regard to the language in which it values of the language in which it v				
	whicl □ in □ pu	report is based on translations from the or h is the language of a translation furnished aternational search (under Rules 12.3 and 2 sublication of the international application (under aternational preliminary examination (under	3.1(b)) nder Rule 12.4)		
2. With regard to the elements* of the international application, this report is based on (replacement she have been furnished to the receiving Office in response to an invitation under Article 14 are referred to report as "originally filed" and are not annexed to this report):					
	Descriptio	on, Pages			
	1-12	as originally filed			
	Claims, N	umbers			
	1-39		05 with letter of 23.12.2004		
	□ a seq	quence listing and/or any related table(s) - s	ee Supplemental Box Relating to Sequence Listing		
3.	☐ the ☐ the ☐ the	amendments have resulted in the cancellat e description, pages e claims, Nos. e drawings, sheets/figs e sequence listing <i>(specify)</i> : ny table(s) related to sequence listing <i>(spec</i>			
4.	had not be Suppleme	report has been established as if (some of) een made, since they have been considered ental Box (Rule 70.2(c)). The description, pages e claims, Nos. The drawings, sheets/figs e sequence listing (specify): The page of the sequence listing (specify) is the sequence of the sequence listing (specify) is the sequence of the sequence	the amendments annexed to this report and listed below d to go beyond the disclosure as filed, as indicated in the		
	* If it	tem 4 applies, some or all of th	ese sheets may be marked "superseded."		

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/IB2004/000536

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

1-3, 5-7,10,13-14.17-18,21,23-26,29,31-33,36-37,39

No: Claims

Inventive step (IS)

1-3, 5-7,10,13-14.17-18,21,23-26,29,31-33,36-37,39

Yes: Claims No: Claims

Industrial applicability (IA)

Yes: Claims

1-3, 5-7,10,13-14.17-18,21,23-26,29,31-33,36-37,39

No: Claims

2. Citations and explanations (Rule 70.7):

see separate sheet

Box No. VII Certain defects in the international application

The following defects in the form or contents of the international application have been noted:

see separate sheet

Re Item V.

1 The following documents are referred to in this communication:

D1: EP 1 004 305 A D2: WO 98/52564 A

Document D1 (see Table III) discloses stable preparations comprising a core including sodium rabeprazole (50 mg) and HPC (450 mg).

Document D2 (see example 3) discloses cores including and active drug and small amounts of low viscosity HPC (HPC-L Klucel). On p. 4, I. 4 pariprazole (= rabeprazole) is disclosed as an example of an active drug.

- The subject-matter of claims 1-3, 5-7, 10, 13-14, 17-18 and 21 (composition); 23-26, 29, 31-33 and 36 (process); and 37 and 39 (method) is novel (Art. 33(2) PCT) since a core comprising rabeprazole and at least 10% w/w of low viscosity HPC has not been disclosed in any of the available prior art documents.
- The subject-matter of claim 1 differs from D1 (see above under item 1) in that it selects a particular HPC, namely low viscosity HPC.

There is no hint in D1 (alone or in combination with any other document) that more stable compositions of rabeprazole can be obtained when including at least 10% w/w of low viscosity HPC in the core. Therefore, the subject-matter of claims 1-3, 5-7, 10, 13-14, 17-18, 21, 23-26, 29, 31-33, 36-37 and 39 is considered to involve an inventive step (Art. 33(3) PCT).

Re Item VII.

1 The claims should be renumbered.

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (SEPARATE SHEET)

International application No.

PCT/IB2004/000536